Aligos director granted 5,860 stock options

Aligos Therapeutics director James Paul Scopa received a new stock option grant covering 5,860 shares of common stock.

Rhea-AI Filing Summary

Aligos Therapeutics director James Paul Scopa received a new stock option grant covering 5,860 shares of common stock. The options have an exercise price of $5.50 per share and expire on June 25, 2036.

The grant vests and becomes fully exercisable as to 100% of the 5,860 shares on the earlier of the first anniversary of the grant date or immediately prior to Aligos Therapeutics' 2027 annual stockholder meeting, provided Scopa continues serving the company through that vesting date. This is a compensation-related award, not an open-market stock purchase or sale.

Insider Trade Summary

Grant/Award: 5,860 shares

Grant/Award 1 txn

Insider Scopa James Paul

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,860	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,860 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

Key Figures

Option grant size: 5,860 options Exercise price: $5.50 per share Expiration date: June 25, 2036 +2 more

5 metrics

Option grant size 5,860 options Shares of common stock underlying new option award

Exercise price $5.50 per share Stock option exercise price for 5,860-share grant

Expiration date June 25, 2036 Option term end date for this grant

Vesting condition 100% on earlier of 1-year or 2027 meeting Subject to continuous service through vesting date

Post-grant derivative holdings 5,860 options Total options held following this reported transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "5.5000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-25T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The shares subject to the option will vest and become exercisable as to 100%..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to continuous service to the Issuer through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aligos Therapeutics (ALGS) director James Paul Scopa report in this Form 4?

Director James Paul Scopa reported receiving a stock option grant for 5,860 shares of Aligos Therapeutics common stock. The award is compensation-related, not an open-market trade, and gives him the right to buy shares at a fixed exercise price if vesting conditions are met.

How many Aligos Therapeutics (ALGS) shares are covered by the new option grant?

The new option grant covers 5,860 shares of Aligos Therapeutics common stock. These options give the director the right to purchase that number of shares once vested, potentially aligning his compensation more closely with the company’s future stock performance.

What is the exercise price of James Paul Scopa’s Aligos Therapeutics (ALGS) stock options?

The stock options have an exercise price of $5.50 per share. This means that once the options vest, Scopa can buy Aligos Therapeutics common shares at $5.50 each, regardless of the market price at that future time.

When do James Paul Scopa’s Aligos Therapeutics (ALGS) options vest?

The options vest 100% on the earlier of the first anniversary of the grant date or immediately before the company’s 2027 annual stockholder meeting. Vesting is conditioned on Scopa maintaining continuous service with Aligos Therapeutics through that chosen vesting date.

When do the newly granted Aligos Therapeutics (ALGS) options to James Paul Scopa expire?

The options expire on June 25, 2036. After that expiration date, any unexercised portion of the 5,860-share option grant will lapse, and Scopa would no longer be able to purchase shares under this particular award.

Is this Aligos Therapeutics (ALGS) Form 4 transaction a market purchase or sale of shares?

No, the Form 4 reports a grant of stock options, not a market trade. It is a compensation-related award giving future purchase rights, rather than Scopa buying or selling Aligos Therapeutics shares on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scopa James Paul

(Last) (First) (Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.5	06/25/2026		A		5,860		(1)	06/25/2036	Common Stock	5,860	$0	5,860	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

	/s/ Lesley Ann Calhoun, as attorney-in fact for James Scopa	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)